Table 1.
Patient characteristics
| Characteristic | KRAS G12C mutations (n = 45), n (%) | KRAS non‐G12C mutations (n = 651), n (%) | p valuea |
|---|---|---|---|
| Age, years, median (range) | 65 (31–79) | 65 (24–88) | .709 |
| Age ≥65 years | 24 (53.3) | 339 (52.1) | .879 |
| Gender | .278 | ||
| Female | 24 (53.3) | 287 (44.1) | |
| Male | 21 (46.7) | 364 (55.9) | |
| ECOG PS | .113 | ||
| 0 | 31 (68.9) | 491 (75.4) | |
| 1 | 9 (20.0) | 133 (20.4) | |
| 2 | 5 (11.1) | 27 (4.1) | |
| Primary tumor location | .776 | ||
| Right | 16 (35.6) | 213 (32.7) | |
| Left | 29 (64.4) | 436 (67.0) | |
| Missing | 0 (0.0) | 2 (0.3) | |
| Surgery on primary tumor | .205 | ||
| Yes | 21 (46.7) | 240 (36.9) | |
| No | 24 (53.3) | 411 (63.1) | |
| Time of first metastasis | .075 | ||
| Metachronous | 10 (22.2) | 233 (35.8) | |
| Synchronous | 35 (77.8) | 418 (64.2) | |
| Histology | .706 | ||
| Well/mod | 40 (88.9) | 581 (89.2) | |
| Poor/muc | 4 (8.9) | 61 (9.4) | |
| Missing | 1 (2.2) | 9 (1.4) | |
| Metastatic sites | |||
| Liver | 30 (66.7) | 375 (57.6) | .275 |
| Lung | 18 (40.0) | 274 (42.1) | .876 |
| Peritoneal dissemination | 16 (35.6) | 150 (23.0) | .070 |
| Number of metastatic sites | .281 | ||
| 1 | 18 (40.0) | 319 (49.0) | |
| ≥2 | 27 (60.0) | 332 (51.0) | |
| Serum LDH, median (range), IU/L | 221 (140–1,459) | 210 (75–4,340) | .515 |
| GPS | .763 | ||
| 0 | 27 (60.0) | 427 (65.6) | |
| 1 | 10 (22.2) | 110 (16.9) | |
| 2 | 7 (15.6) | 105 (16.1) | |
| Missing | 1 (2.2) | 9 (1.4) | |
| First‐line backbone regimen | .357 | ||
| Monob | 2 (4.4) | 32 (4.9) | |
| Doubletc | 43 (95.6) | 591 (90.8) | |
| Tripletd | 0 (0.0) | 28 (4.3) | |
| First‐line bevacizumab | .843 | ||
| Yes | 36 (80.0) | 531 (81.6) | |
| No | 9 (20.0) | 120 (18.5) |
a
Values of p were calculated using Fisher's exact probability test for categorical variables.
b
Mono indicates 5‐fluorouracil (5‐FU)/leucovorin (LV), capecitabine, tegafur‐uracil (UFT)/LV, or S‐1 monotherapy.
c
Doublet indicates oxaliplatin‐based regimens (FOLFOX, CAPOX, and SOX) or irinotecan‐based regimens (FOLFIRI, IRIS [SIRB], CAPIRI).
d
Triplet indicates FOLFOXIRI.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; GPS, Glasgow prognostic score; KRAS, Kirsten rat sarcoma; LDH, lactate dehydrogenase; mod, moderately differentiated; muc, mucinous adenocarcinoma; por, poorly differentiated; well, well differentiated.